Strategic Wealth Partners Ltd. Trims Stake in Pfizer Inc. (NYSE:PFE)

Strategic Wealth Partners Ltd. lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 22.1% during the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 30,035 shares of the biopharmaceutical company’s stock after selling 8,513 shares during the period. Strategic Wealth Partners Ltd.’s holdings in Pfizer were worth $1,301,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Stone Ridge Asset Management LLC grew its holdings in Pfizer by 399.2% in the second quarter. Stone Ridge Asset Management LLC now owns 29,012 shares of the biopharmaceutical company’s stock worth $1,257,000 after purchasing an additional 23,200 shares during the period. Payden & Rygel grew its holdings in Pfizer by 9.4% in the second quarter. Payden & Rygel now owns 883,870 shares of the biopharmaceutical company’s stock worth $38,289,000 after purchasing an additional 75,700 shares during the period. Cynosure Management LLC purchased a new stake in Pfizer in the second quarter worth about $556,000. Meristem Family Wealth LLC grew its holdings in Pfizer by 22.1% in the second quarter. Meristem Family Wealth LLC now owns 41,512 shares of the biopharmaceutical company’s stock worth $1,798,000 after purchasing an additional 7,508 shares during the period. Finally, Good Life Advisors LLC grew its holdings in Pfizer by 3.7% in the second quarter. Good Life Advisors LLC now owns 24,575 shares of the biopharmaceutical company’s stock worth $1,070,000 after purchasing an additional 873 shares during the period. Institutional investors own 71.58% of the company’s stock.

A number of equities research analysts have weighed in on the stock. Barclays restated a “hold” rating and issued a $41.00 price objective on shares of Pfizer in a report on Thursday, May 9th. UBS Group restated a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a report on Monday, August 5th. JPMorgan Chase & Co. set a $46.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Monday, July 29th. Goldman Sachs Group reiterated a “buy” rating and set a $49.00 price target on shares of Pfizer in a report on Monday, June 17th. Finally, Bank of America cut shares of Pfizer from a “buy” rating to a “neutral” rating in a report on Tuesday, July 30th. Fourteen investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $46.67.

In other news, EVP Frank A. Damelio sold 153,184 shares of the firm’s stock in a transaction on Tuesday, July 2nd. The shares were sold at an average price of $44.09, for a total transaction of $6,753,882.56. Following the sale, the executive vice president now directly owns 489,647 shares in the company, valued at approximately $21,588,536.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 30,000 shares of the firm’s stock in a transaction on Thursday, June 20th. The shares were sold at an average price of $44.00, for a total transaction of $1,320,000.00. Following the sale, the insider now owns 80,094 shares in the company, valued at $3,524,136. The disclosure for this sale can be found here. 0.09% of the stock is owned by corporate insiders.

Pfizer stock traded down $0.74 during midday trading on Friday, reaching $34.34. 20,323,181 shares of the company traded hands, compared to its average volume of 35,302,192. The firm has a market capitalization of $194.03 billion, a price-to-earnings ratio of 11.45, a price-to-earnings-growth ratio of 2.80 and a beta of 0.63. The business has a 50 day moving average of $39.60 and a two-hundred day moving average of $41.43. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $46.47. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. The company had revenue of $13.26 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.77 earnings per share. As a group, equities analysts forecast that Pfizer Inc. will post 2.8 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, August 2nd will be given a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, August 1st. This represents a $1.44 dividend on an annualized basis and a yield of 4.19%. Pfizer’s dividend payout ratio (DPR) is 48.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: Moving Average – How it Helps Investors in Stock Selection

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.